ÂÜŔňÂŇÂ×

Marian Nakada has almost 30 years of experience in the pharmaceutical industry, starting her career at the laboratory bench at Centocor and moving to a research leadership role before Centocor’s acquisition by Johnson & Johnson in 1999.

She transitioned to Janssen Business Development where she executed deals to support the expansion of the Biologics portfolio. She joined JJDC, Johnson & Johnson’s corporate venture group, in 2013 and some of her investments include Padlock Therapeutics, CoStim Pharmaceuticals, and Vedanta Biosciences. She is passionate about leveraging Johnson & Johnson’s capabilities to help her portfolio companies succeed. Marian has a B.A. in Biology from Harvard College and a Ph.D. in Pharmacology from the University of Pennsylvania. She is currently on the Boards of Navitor Pharmaceuticals, Twenty-eight Seven Therapeutics, Ribon Therapeutics, Artizan Biosciences as well as the New England Venture Capital Association where she is working to champion change as an active contributor to its Diversity & Inclusion Committee.